Home » Sorrento Therapeutics Releases Positive Results from Asthma Trial
Sorrento Therapeutics Releases Positive Results from Asthma Trial
Sorrento Therapeutics has released positive data from a combination Phase 2/Phase 3 clinical study in China evaluating its STI-004 biosimilar of Genentech’s Xolair in patients suffering from allergic asthma.
The candidate reached its primary endpoint of reducing asthma exacerbations, with 21 percent of patients taking STI-004 experiencing asthma exacerbation versus 55 percent in the placebo group.
Upcoming Events
-
07May
-
14May
-
30May